Finally, prexasertinib, a selective CHK1 inhibitor, was investigated as a single-agent in a phase II trial in patients with pre-treated ED-SCLC, but it failed to demonstrate beneficial activity [103]. Here, CHEK1 is linked to small cell lung carcinoma.